Ventyx Biosciences Inc
VTYX2.695USD
+0.065+2.47%
交易中 （美东）报价延迟15分钟
191.78M总市值
亏损市盈率 TTM
关于 Ventyx Biosciences Inc 公司
Ventyx Biosciences, Inc. 是一家临床阶段生物制药公司。该公司专注于开发一系列小分子候选产品，以解决一系列尚未得到满足的炎症疾病需求。该公司的产品线包括 VTX002（S1P1R 调节剂）、VTX958（TYK2 抑制剂）以及 VTX2735 和 VTX3232（NLRP3 抑制剂组合）。VTX002 是一种鞘氨醇 1 磷酸受体 (S1P1R) 调节剂，目前处于 II 期开发阶段，用于治疗中度至重度活动性溃疡性结肠炎 (UC) 患者。VTX958 是一种口服、选择性临床阶段酪氨酸激酶 2 型 (TYK2) 抑制剂，TYK2 是 Janus 激酶 (JAK) 家族中的一种细胞内信号激酶，可调节免疫介导疾病中的慢性炎症。该公司的第三款候选产品 VTX2735 是一种针对外周的 NOD 样受体蛋白 3 (NLRP3) 炎症小体抑制剂。除了 VTX2735，该公司还在开发 VTX3232，这是该公司处于第 1 阶段开发中的领先 CNS 渗透性 NLRP3 抑制剂。
公司简介
公司代码VTYX
公司名称Ventyx Biosciences Inc
上市日期Oct 21, 2021
CEOMr. Raju Mohan, Ph.D.
员工数量79
证券类型Ordinary Share
年结日Oct 21
公司地址12790 El Camino Real, Suite 200
城市SAN DIEGO
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编92130
电话18589452393
网址https://ventyxbio.com/
公司代码VTYX
上市日期Oct 21, 2021
CEOMr. Raju Mohan, Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Raju Mohan, Ph.D.
Mr. Raju Mohan, Ph.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
2.30M
--
Dr. Sheila Gujrathi, M.D.
Dr. Sheila Gujrathi, M.D.
Executive Chairperson of the Board
Executive Chairperson of the Board
130.00K
--
Dr. John M. Nuss, Ph.D.
Dr. John M. Nuss, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Somasundaram Subramaniam
Mr. Somasundaram Subramaniam
Independent Director
Independent Director
--
--
Dr. Allison J. Hulme, Ph.D.
Dr. Allison J. Hulme, Ph.D.
Independent Director
Independent Director
--
--
Dr. Mark Forman, M.D., Ph.D.
Dr. Mark Forman, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Roy M. Gonzales
Mr. Roy M. Gonzales
Senior Vice President - Finance
Senior Vice President - Finance
--
--
Mr. William R. White, J.D.
Mr. William R. White, J.D.
Independent Director
Independent Director
--
--
Ms. Onaiza Cadoret - Manier
Ms. Onaiza Cadoret - Manier
Independent Director
Independent Director
--
--
Mr. Matthew (Matt) Moore
Mr. Matthew (Matt) Moore
Chief Operating Officer
Chief Operating Officer
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Raju Mohan, Ph.D.
Mr. Raju Mohan, Ph.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
2.30M
--
Dr. Sheila Gujrathi, M.D.
Dr. Sheila Gujrathi, M.D.
Executive Chairperson of the Board
Executive Chairperson of the Board
130.00K
--
Dr. John M. Nuss, Ph.D.
Dr. John M. Nuss, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Somasundaram Subramaniam
Mr. Somasundaram Subramaniam
Independent Director
Independent Director
--
--
Dr. Allison J. Hulme, Ph.D.
Dr. Allison J. Hulme, Ph.D.
Independent Director
Independent Director
--
--
Dr. Mark Forman, M.D., Ph.D.
Dr. Mark Forman, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 6月1日 周日
更新时间: 6月1日 周日
持股股东
股东类型
持股股东
持股股东
占比
Point72 Asset Management, L.P.
5.95%
Affinity Asset Advisors LLC
5.70%
BlackRock Institutional Trust Company, N.A.
5.69%
New Science Ventures, LLC
5.67%
The Vanguard Group, Inc.
4.94%
Other
72.05%
持股股东
持股股东
占比
Point72 Asset Management, L.P.
5.95%
Affinity Asset Advisors LLC
5.70%
BlackRock Institutional Trust Company, N.A.
5.69%
New Science Ventures, LLC
5.67%
The Vanguard Group, Inc.
4.94%
Other
72.05%
股东类型
持股股东
占比
Hedge Fund
29.49%
Investment Advisor
18.75%
Investment Advisor/Hedge Fund
16.10%
Venture Capital
5.74%
Individual Investor
4.12%
Research Firm
3.60%
Family Office
0.27%
Bank and Trust
0.17%
Pension Fund
0.07%
Other
21.71%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
365
55.53M
78.03%
-48.49M
2025Q1
385
51.70M
72.65%
-54.51M
2024Q4
397
65.14M
91.63%
-35.16M
2024Q3
387
62.43M
88.32%
-37.01M
2024Q2
376
67.39M
95.54%
-30.30M
2024Q1
369
70.49M
100.19%
-8.56M
2023Q4
345
54.61M
92.50%
-19.94M
2023Q3
315
66.31M
112.60%
-5.18M
2023Q2
302
65.66M
112.13%
-3.35M
2023Q1
267
64.47M
110.86%
+4.32M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Point72 Asset Management, L.P.
4.23M
5.95%
+2.45M
+137.64%
Mar 31, 2025
Affinity Asset Advisors LLC
4.06M
5.7%
+4.06M
--
May 22, 2025
BlackRock Institutional Trust Company, N.A.
4.05M
5.69%
-66.25K
-1.61%
Mar 31, 2025
New Science Ventures, LLC
4.03M
5.67%
-3.07M
-43.23%
Mar 28, 2025
The Vanguard Group, Inc.
3.51M
4.94%
+5.11K
+0.15%
Mar 31, 2025
Tang Capital Management, LLC
3.10M
4.36%
--
--
Mar 31, 2025
Sio Capital Management, LLC
2.58M
3.63%
-1.46M
-36.18%
Mar 31, 2025
Mohan (Raju)
2.30M
3.24%
--
--
Apr 10, 2025
Vestal Point Capital, LP
2.00M
2.81%
--
--
Mar 31, 2025
Redmile Group, LLC
1.57M
2.21%
+1.45M
+1164.15%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Invesco NASDAQ Future Gen 200 ETF
0.57%
iShares Micro-Cap ETF
0.03%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
Invesco Nasdaq Biotechnology ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
Fidelity MSCI Health Care Index ETF
0%
DFA Dimensional US Core Equity Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Biotechnology ETF
0%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0%
查看更多
Invesco NASDAQ Future Gen 200 ETF
占比0.57%
iShares Micro-Cap ETF
占比0.03%
Invesco RAFI US 1500 Small-Mid ETF
占比0.01%
Invesco Nasdaq Biotechnology ETF
占比0%
ProShares Ultra Nasdaq Biotechnology
占比0%
Fidelity MSCI Health Care Index ETF
占比0%
DFA Dimensional US Core Equity Market ETF
占比0%
iShares Core S&P Total U.S. Stock Market ETF
占比0%
iShares Biotechnology ETF
占比0%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
